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BACKGROUND: Mitral annular calcification (MAC) is associated with 
cardiovascular events and mitral valve dysfunction. However, the 
underlying pathophysiology remains incompletely understood. In this 
prospective longitudinal study, we used a multimodality approach 
including positron emission tomography, computed tomography, and 
echocardiography to investigate the pathophysiology of MAC and assess 
factors associated with disease activity and progression.
METHODS: A total of 104 patients (age 72±8 years, 30% women) with 
calcific aortic valve disease, therefore predisposed to MAC, underwent 
18F-sodium fluoride (calcification activity) and 18F-Fluorodeoxyglucose 
(inflammation activity) positron emission tomography, computed 
tomography calcium scoring, and echocardiography. Sixty patients 
underwent repeat computed tomography and echocardiography after 2 
years.
RESULTS: MAC (mitral annular calcium score >0) was present in 35 
(33.7%) patients who had increased 18F-fluoride (tissue-to-background 
ratio, 2.32 [95% CI, 1.81–3.27] versus 1.30 [1.22–1.49]; P<0.001) and 
18F-Fluorodeoxyglucose activity (tissue-to-background ratio, 1.44 [1.37–
1.58] versus 1.17 [1.12–1.24]; P<0.001) compared with patients without 
MAC. MAC activity (18F-fluoride uptake) was closely associated with the 
local calcium score and 18F-Fluorodeoxyglucose uptake, as well as female 
sex and renal function. Similarly, MAC progression was closely associated 
with local factors, in particular, baseline MAC. Traditional cardiovascular 
risk factors and calcification activity in bone or remote atherosclerotic 
areas were not associated with disease activity nor progression.
CONCLUSIONS: MAC is characterized by increased local calcification 
activity and inflammation. Baseline MAC burden was associated with 
disease activity and the rate of subsequent progression. This suggests a 
self-perpetuating cycle of calcification and inflammation that may be the 
target of future therapeutic interventions.
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Mitral annular calcification (MAC) is a common finding on cardiovascular imaging studies with an estimated prevalence ranging from 8% to 
42% depending on age of the population studied and 
analysis method.1,2 Often associated with aortic, coro-
nary artery, and aortic valve calcification (AVC),2 MAC 
has been linked to increased atherosclerotic burden,2 
incident stroke,3 and cardiovascular mortality.4 Al-
though MAC is associated with endothelial damage, 
lipid infiltration, and progressive valve calcification,5–7 
the pathophysiology of MAC remains incompletely un-
derstood and medical therapies to halt its progression 
are lacking. MAC also has functional consequences, 
helping to drive progressive mitral stenosis and mitral 
regurgitation, the severe stages of which can only be 
remedied through surgical or, potentially, percutane-
ous intervention.8,9
Several epidemiological studies have investigated 
risk factors for MAC, finding similar determinants as 
for calcific aortic valve disease, including age, obesity, 
smoking, and serum phosphate.10,11 Important differ-
ences have also been observed, with MAC showing 
female predominance7 and a stronger association 
with chronic kidney disease and dysregulated mineral 
metabolism.12,13 An association with low bone min-
eral density (BMD) has been suggested but remains 
unproven.14 Despite the various investigations into 
risk factors for MAC incidence and prevalence, no 
studies to date have evaluated risk factors governing 
disease activity.
Hybrid positron emission and computed tomography 
(PET-CT) allows for the simultaneous noninvasive eval-
uation of disease activity and heart valve anatomy.15,16 
CT provides a detailed assessment of calcium burden, 
and PET can measure the activity of specific disease pro-
cesses dependent on the availability of suitable tracers. 
18F-Sodium fluoride (18F-fluoride) is a marker of vascular 
and valvular calcification activity17 that has been used 
to investigate vascular atherosclerosis and aortic steno-
sis.15,18 18F-Fluorodeoxyglucose (18F-FDG) has been used 
to measure vascular inflammation because of its accu-
mulation within tissue macrophages.19
In this clinical imaging study, our aim was to use a 
state-of-the-art multimodality imaging approach to 
investigate activity and inflammation to elucidate fac-
tors associated with disease prevalence, activity, and 
progression.
METHODS
Patients aged >50 years with calcific aortic valve disease were 
recruited as previously described and formed the study co-
hort.15 All had AVC on CT and were, therefore, deemed prone 
to developing calcific valve disease. Exclusion criteria included 
insulin-dependent diabetes mellitus, blood glucose >200 
mg/dL, end-stage renal disease, metastatic malignancy, and 
life expectancy <2 years. The study cohort was divided into 
patients who did (score>0) or did not (score=0) have MAC 
on CT to assess factors associated with MAC prevalence. 
Clinical data were ascertained based on detailed history and 
clinical examination. Fasting serum biomarkers were analyzed 
as previously described. Lipoprotein(a) was measured using 
chemiluminescent immunoassays as previously described.20 
A detailed echocardiographic exam was performed under 
standardized conditions according to a formal protocol as 
previously described.15 The Institutional Review Board of the 
University of Edinburgh approved the protocol, and partici-
pants provided written informed consent. Study data can be 
made available to other researchers on request to the corre-
sponding author.
A control cohort without evidence of heart valve calci-
fication (CT calcium score of 0 in mitral annulus and aortic 
valve) was also included to determine the normal range of 
18F-fluoride PET uptake in the mitral annulus, with the high-
est 18F-fluoride tissue-to-background ratio (TBRmax) values de-
fining the upper limit of normal and differentiating between 
study cohort patients who did (PET+) and did not have (PET−) 
increased PET activity.
CLINICAL PERSPECTIVE
Mitral annular calcification (MAC) is associated 
with cardiovascular events and mitral valve dys-
function, but its pathophysiology is incompletely 
understood. We employed a multimodality im-
aging approach including 18F-fluorodeoxyglucose 
and 18F-sodium fluoride positron emission tomog-
raphy, computed tomography calcium scoring, and 
echocardiography to investigate the pathology of 
MAC and elucidate the factors associated with its 
prevalence, disease activity, and disease progres-
sion. Patients who had MAC (34% of patients) had 
increased inflammatory and calcification activity by 
positron emission tomography imaging in the mi-
tral annulus. Furthermore, calcification activity was 
most closely associated with computed tomogra-
phy-MAC calcium score, inflammation, female sex, 
and renal dysfunction. Similarly, MAC progression 
on repeat computed tomography scans after 2 
years was closely associated with baseline MAC, 
with the fastest rate of progression found in those 
with high baseline computed tomography-MAC 
scores and the highest calcification activity. By con-
trast, traditional cardiovascular risk factors and cal-
cification activity in bone or remote atherosclerotic 
areas were not associated with disease activity nor 
progression. This suggests that MAC activity and 
progression are characterized by a vicious cycle 
of established calcium, injury and inflammation 
within the valve that prompts further calcification 
activity. These findings support the concept that 
therapeutic strategies targeting MAC will need to 
focus on breaking this vicious calcification cycle.
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PET-CT Imaging
PET-CT scans of the heart and aorta were performed with 
a hybrid scanner (Biograph mCT, Siemens Medical Systems, 
Erlangen, Germany). Two scans were performed at least 24 
hours apart, 60 minutes after administration of 18F-fluoride 
125 MBq and 90 minutes after 18F-FDG 200 MBq. ECG-
gating was not used, and all counts were used for analysis. 
All patients were asked to adhere to a carbohydrate-free diet 
for 24 hours preceding their 18F-FDG scan to suppress myo-
cardial uptake, as previously described.15 Patients were given 
a list of foods (high in fat and low in carbohydrate) to eat 
and also those to avoid. An ECG-gated breath-hold CT scan 
(noncontrast-enhanced, 40 mA/rot [CareDose], 100 kV) of 
the heart was performed for calcium scoring.
Image Analysis: CT
Mitral annulus, aortic valve, coronary artery, and aortic CT 
calcium scores were determined using dedicated analysis 
software (VScore, Vital Images, Minnetonka, and OsiriX Lite 
version 8.5.1, OsiriX Imaging Software, Geneva, Switzerland). 
Agatston scores were calculated using a threshold of 130 
Hounsfield units.21 MAC on (CT-MAC) was defined as calcium 
score >0 Agatston units (AU) in the mitral annulus.
Image Analysis: PET
Mitral annular 18F-fluoride and 18F-FDG PET activity were 
quantified according to a standardized protocol using OsiriX. 
Regions of interest were drawn around maximal areas of 
18F-fluoride and 18F-FDG activity to obtain the maximum stan-
dardized uptake values (SUVmax), which were divided by blood 
pool uptake values in the right atrium (2 cm2 area) to obtain 
TBRmax values. Given the difficulty in determining the exact 
borders of the mitral annulus, SUVmean, and TBRmean values 
were not quantified.
Uptake of 18F-fluoride and 18F-FDG in the aortic valve, aorta, 
and coronary arteries was measured as previously reported 
(Data Supplement).15 BMD and 18F-fluoride bone uptake were 
measured in 4 thoracic vertebrae as detailed previously.18 
Briefly, 0.5 cm2 regions of interest were drawn within the can-
cellous bone. The average Hounsfield unit density within those 
regions was used as a relative measure of BMD.22 Maximum 
18F-fluoride SUV values were quantified in the same regions of 
interest. Myocardial 18F-FDG uptake was assessed by recording 
the maximum SUV in the left ventricular septum. A diffuse 
pattern of myocardial 18F-FDG uptake accompanied by SUV 
≥5.0 indicated failed myocardial suppression.15 Patients with 
failed suppression were excluded from the analysis of FDG 
data, but not from analysis of 18F-fluoride data.
Repeatability Studies
All CT and PET quantifications were independently performed 
in a blinded fashion by 2 trained observers (M.G. Trivieri and 
D. Massera). Disagreements were resolved by consensus with 
involvement of a third observer (R. Abgral).
Image Analysis: Echocardiography
Examination of the mitral valve apparatus was performed in 
a blinded fashion by one cardiologist (J. Andrews). At least 
3 diastolic transmitral continuous-wave Doppler envelopes 
were traced to obtain an average diastolic transmitral gra-
dient. Mitral regurgitation severity was assessed according to 
the American Society of Echocardiography guidelines.23 No 
adjustment for heart rate was performed because 87% of 
patients had a heart rate of <80 bpm.
Disease Progression Studies
A subset of study participants underwent repeat CT and echo-
cardiography using the same protocol and equipment 2 years 
after initial imaging. Mitral annular disease progression was 
assessed using the annualized change in CT calcium score and 
transmitral pressure gradient.
Statistical Analysis
Continuous variables are reported as mean±SD or median 
(interquartile range [IQR]) and were compared with the un-
paired Student t test, Wilcoxon rank-sum or Kruskal-Wallis 
tests, as appropriate. Categorical variables are reported as 
proportions and analyzed with the χ2 or Fishers exact test. 
Correlations were calculated using Spearman correlation 
coefficients. Data are presented by presence or absence 
of CT-MAC or mitral annular 18F-fluoride activity or were 
dichotomized at the median CT-MAC calcium score. Bland-
Altman mean differences and limits of agreement were 
obtained. Intraclass correlation coefficients were calculated 
with 2-way mixed-effects models. Multivariable linear and 
logistic regression models were used to identify predictors of 
MAC prevalence and 18F-fluoride activity. Logarithmic trans-
formation of 18F-fluoride uptake was performed to achieve 
a normal distribution. Initially, all variables with P<0.2 in 
bivariate comparisons were included in the model, as well 
as important cardiovascular risk factors (age, sex, hyperten-
sion, diabetes mellitus, smoking, low-density lipoprotein 
cholesterol, and prior cardiovascular disease). Subsequently, 
a backward stepwise selection process was used with age 
and sex forced into the model. Separately, 18F-FDG TBRmax 
was added to the model to identify FDG as a predictor of 
18F-fluoride uptake. Multiple linear and multinomial logistic 
regression models were used to identify predictors of MAC 
progression. All analyses were performed with STATA 14.2 
(StataCorp LP, College Station, TX). A 2-tailed P<0.05 was 
used to define statistical significance.
RESULTS
Patient Population
The study cohort comprised 104 patients (mean age 
72±8 years, 30% women; baseline characteristics are 
presented in Tables 1 and 2). The median transmitral 
mean diastolic pressure gradient was 1.4 (IQR, 1.0–2.1) 
mm Hg (Data Supplement). In addition, a control co-
hort of 17 subjects without heart valve calcification was 
included (68±8 years; Data Supplement). The effec-
tive radiation dose per patient was 9.7±1.2 mSv (CT 
conversion factor 0.014 mSv/mGy/cm). Interobserver 
reproducibility for MAC-CT calcium scoring (intraclass 
coefficient, 1.00 [95% CI, 0.99–1.00]) and PET quantifi-
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cation (18F-fluoride TBRmax 0.99 [0.98–0.99] and 
18F-FDG 
TBRmax 0.87 [0.82–0.91]) was good (Data Supplement).
Factors Associated with MAC Prevalence
The median baseline MAC-CT calcium score was 0 (IQR, 
0–316) AU and was higher in women (283 [0–1082] 
AU) compared with men (0 [0–0] AU; P=0.001). Over-
all, 35 (33.7%) patients had MAC on CT (CT+; 837 
[300–2129] AU), who were older, twice as likely to be 
female, had more AVC, lower BMD, and reduced esti-
mated glomerular filtration rate (eGFR) compared with 
patients without MAC (CT−). Both groups had exten-
sive cardiovascular disease risk factor burden (Table 1). 
In a multiple logistic regression model, female sex and 
AVC calcium score were statistically significantly associ-
ated with MAC prevalence (Table 3).
Mitral Annular Inflammatory Activity 
(18F-FDG PET)
Thirty-three patients (32%) met criteria for failed myo-
cardial suppression of physiological 18F-FDG uptake and 
were excluded from further analysis of FDG data only. In 
the remaining patients, median mitral annular 18F-FDG 
TBRmax was 1.21 (IQR, 1.14–1.39), higher in patients 
with CT-MAC (CT+ 1.44 [1.37–1.58]) compared with 
those without (CT− 1.17 [1.12–1.24]; P<0.001) or with 
controls (1.06 [1.04–1.17]; P<0.001). A moderate cor-
relation was observed between mitral annular 18F-FDG 
TBRmax and CT-MAC scores (r=0.50, P<0.001; Table 4).
Mitral annular 18F-FDG TBRmax uptake was negatively 
correlated with total cholesterol and low-density lipopro-
tein (r=−0.30; P=0.014) and was higher in women (1.33 
[1.16–1.45]) than men (1.19 [1.12–1.32]; P=0.037); there 
was no correlation with other serum biomarkers nor 
18F-FDG activity measured in remote areas (aortic valve, 
r=−0.05, P=0.658; aorta, r=−0.23, P=0.060; Table 4).
MAC Activity (18F-Fluoride PET)
Median mitral annular 18F-fluoride TBRmax uptake in the 
entire study cohort (104 patients) was 1.44 (IQR, 1.27–
1.89). Patients with CT-MAC had higher 18F-fluoride 
uptake (CT+ 2.32 [1.81–3.27]) than those without (CT− 
1.30 [1.22–1.49]; P<0.001). Mitral annular 18F-fluoride 
activity appeared most closely related to local markers 
of disease burden. A strong correlation was observed 
Table 1. Baseline Characteristics by Presence of Mitral Annular Calcification (Prevalence) and Mitral Annular 18F-Fluoride Uptake 
(Disease Activity)
Baseline Characteristics MAC−, (n=69) MAC+, (n=35) P Value
18F-Fluoride−, 
(n=66)
18F-Fluoride+ 
(n=36) P Value
Age, years 70.6±7.9 75.1±8.2 0.011 70.8±7.9 74.8±8.7 0.026
Female, n (%) 14 (20.3) 17 (48.6) 0.003 12 (18.2) 19 (52.8) <0.001
Body mass index, kg/m2 27.6±4.2 28.7±4.9 0.276 27.4±3.9 28.9±5.0 0.093
Ischemic heart disease, n (%) 27 (39.1) 11 (31.4) 0.441 28 (42.4) 9 (25.0) 0.080
Cardiovascular disease, n (%) 31 (44.9) 11 (31.4) 0.185 32 (48.9) 9 (25.0) 0.021
Current smoking, n (%) 8 (11.6) 4 (11.4) 0.980 7 (10.6) 4 (11.1) 0.937
Diabetes mellitus, n (%) 9 (13.2) 6 (17.1) 0.594 9 (13.9) 6 (16.7) 0.703
Hypertension, n (%) 41 (59.4) 23 (65.7) 0.533 39 (59.1) 23 (63.9) 0.635
Osteoporosis, n (%) 2 (2.9) 0 (0) 0.309 2 (3.0) 0 (0) 0.539
Bone mineral density (mean, HU) 160.6±43.2 142.1±38.5 0.035 159.7±41.0 144.8±43.6 0.096
eGFR, mL/min/1.73m2 74.5±17.8 63.5±18.9 0.004 73.0±17.6 67.0±20.1 0.121
Urea, mg/dL 20.0±7.1 22.3±7.7 0.159 20.0±5.5 22.4±9.8 0.187
Calcium, mg/dL 9.3±0.7 9.4±0.3 0.119 9.2±0.5 9.5±0.7 0.047
Phosphate, mg/dL 3.6±1.1 3.5±0.5 0.606 3.5±0.5 3.7±1.4 0.411
Alkaline phosphatase, U/dL 78.7±20.2 99.1±74.9 0.133 80.2±22.9 95.6±74.3 0.255
Total cholesterol, mg/dL 195.6±52.6 183.8±51.5 0.280 190.2±50.1 193.2±56.2 0.781
LDL cholesterol, mg/dL 107.4±44.4 101.0±46.2 0.511 101.1±41.2 110.6±49.2 0.307
HDL cholesterol, mg/dL 55.4±23.2 50.4±12.0 0.146 55.8±23.4 50.5±12.4 0.133
Triglycerides, mg/dL 75.7±47.2 70.7±37.1 0.554 76.0±46.6 71.5±39.6 0.621
Lipoprotein(a), ng/dL 18.6 (8.9–62.9) 18.1 (9.0–54.9) 0.845 17.6 (8.3–67.4) 20.5 (9.0–55.6) 0.660
Statin therapy, n (%) 39 (56.5) 521 (60.0) 0.734 40 (60.6) 18 (50.0) 0.301
ACE inhibitor therapy, n (%) 27 (39.1) 14 (40.0) 0.932 26 (39.4) 14 (38.9) 0.960
Continuous variables are presented as mean±SD or median (IQR). eGFR indicates estimated glomerular filtration rate (CKD-EPI); HDL, high-
densty lipoprotein; LDL, low-density lipoprotein; and MAC, mitral annular calcification.
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between mitral annular 18F-fluoride activity and base-
line CT-MAC score (r=0.79, P<0.001; Figure 1A) while a 
moderate correlation was observed with 18F-FDG uptake 
(r=0.32, P=0.001; Figure  1B). By comparison, modest 
or no correlations were observed between mitral annu-
lar 18F-fluoride uptake and uptake in other areas (aorta, 
r=0.23, P=0.025; aortic valve, r=0.19, P=0.053; coronary 
arteries, r=0.14, P=0.159; and bone, r=0.02, P=0.861) 
or serum biomarkers including calcium, alkaline phos-
phatase, and lipid markers (Table  3). Mitral annular 
18F-fluoride uptake was higher in women compared 
with men (2.01 [1.31–2.69] versus 1.36 [1.26–1.63]; 
P=0.002), and in patients with impaired (eGFR<60 mL/
min/1.73m2) compared with preserved renal function 
(1.39 [1.10–1.61] versus 1.26 [1.04–1.36]; P=0.046).
Among the control cohort, the highest 18F-fluoride 
TBRmax value was 1.64. This cutoff was used to cate-
gorize patients in the study cohort as having increased 
18F-fluoride uptake (>1.64, PET+) or not (≤1.64, PET−). 
Overall, 36 (35.6%) patients had increased 18F-fluo-
ride uptake (median TBRmax, 2.30 [1.84–3.07]). PET+ 
patients had a median CT-MAC calcium score of 834 
(139–2107), while PET− patients had no MAC (Fig-
ure 1C). Compared with PET− patients, PET+ patients 
were older, more likely to be female, had more AVC, 
lower BMD, and eGFR (Table  1). In a multiple linear 
regression model, CT-MAC and AVC calcium scores, 
female sex, and eGFR demonstrated a statistically sig-
nificant association with MAC disease activity. When 
18F-FDG TBRmax was added to the model, significant pre-
dictors of MAC 18F-fluoride activity were baseline CT-
MAC and 18F-FDG TBRmax in the subset of patients with 
successful myocardial suppression (Table 5).
Disease Progression in Mitral Annular 
Calcification
Sixty patients in the study cohort underwent repeat 
echocardiography and CT after a median of 741 
(IQR, 726–751) days (Figure  2 includes examples of 
3 patients). The annual progression rate of CT-MAC 
calcium score was 2 (0–166) AU per year. The strong-
est associations of MAC progression were observed 
with baseline CT-MAC (r=0.82, P<0.001; Figure  3A), 
18F-fluoride (r=0.75, P<0.001; Figure  3B) and 18F-FDG 
activity (r=0.48; P<0.002). Women tended to have 
a higher rate of MAC progression (34 [0–409] AU/y) 
than men (0 [0–68] AU/y; P=0.083). There was no as-
sociation between baseline eGFR and MAC progression 
(r=−0.13; P=0.308) nor differences in the rate of MAC 
progression between those with and without advanced 
Table 2. Imaging Characteristics by Presence of Mitral Annular Calcification (Prevalence) and Mitral Annular 18F-Fluoride Uptake (Disease Activity)
Imaging Characteristics MAC−, (n=69) MAC+, (n=35) P Value
18F-Fluoride−, 
(n=66) 18F-Fluoride+, (n=36) P Value
Aortic valve by echocardiography
Control, n (%) 3 (4.4) 2 (5.7) 0.034 4 (6.1) 1 (2.8) 0.012
Sclerosis, n (%) 16 (23.3) 2 (5.7)  17 (25.8) 1 (2.8)  
Mild stenosis, n (%) 20 (29.0) 5 (14.3)  17 (25.8) 7 (19.4)  
Moderate stenosis, n (%) 18 (26.1) 15 (42.9)  18 (27.3) 15 (41.7)  
Severe stenosis, n (%) 12 (17.4) 11 (31.4)  10 (15.2) 12 (33.3)  
AVC calcium score, AU 801 (298–2174) 1501 (600–3314) 0.030 771 (309–2076) 1598 (1007–3230) 0.003
MAC calcium score, AU 0 837 (300–2129) … 0 834 (139–2107) …
Aorta calcium score, AU 894 (190–2548) 1733 (396–7984) 0.058 997 (144–3181) 1378 (374–4036) 0.170
Aortic valve 18F-fluoride TBRmax 2.44 (1.91–2.99) 2.58 (2.21–3.14) 0.192 2.34 (1.96–2.91) 2.74 (2.38–3.18) 0.028
Mitral annulus 18F-fluoride TBRmax 1.30 (1.22–1.49) 2.32 (1.81–3.27) <0.001 1.29 (1.22–1.41) 2.30 (1.84–3.07) <0.001
Coronary artery18F fluoride TBRmax 1.50 (1.33–1.75) 1.60 (1.35–2.09) 0.274 1.50 (1.35–1.76) 1.59 (1.35–2.02) 0.590
18F-fluoride TBRmax in aorta 2.06 (1.82–2.28) 2.14 (1.19–2.38) 0.081 2.05 (1.84–2.26) 2.20 (1.91–2.50) 0.060
Aortic valve 18F-FDG TBRmax * 1.52 (1.44–1.63) 1.39 (1.33–1.63) 0.072 1.51 (1.40–1.63) 1.46 (1.35–1.68) 0.83
Mitral annulus 18F-FDG TBRmax * 1.17 (1.12–1.24) 1.44 (1.37–1.58) <0.001 1.17 (1.12–1.26) 1.38 (1.24–1.56) 0.002
Aorta 18F-FDG TBRmax 1.84 (1.69–1.94) 1.68 (1.50–1.78) 0.002 1.83 (1.68–1.92) 1.69 (1.61–1.83) 0.116
Continuous variables are presented as median (IQR). AVC indicates aortic valve calcification; 18F-FDG, 18F-Fluorodeoxyglucose; MAC, mitral annular calcification; 
and TBRmax, tissue-to-background ratio.
* n=33 patient with failed myocardial FDG suppression were excluded.
Table 3. Factors Associated With MAC Prevalence in a Multiple 
Logistic Regression Model
 OR 95% CI P Value
Age (per 10 y) 1.29 0.67–2.50 0.45
Male sex 0.25 0.11–0.75 0.01
Aortic valve calcium (per 
100 AU increase)
1.03 1.00–1.06 0.03
eGFR (per 10 mL/min) 0.77 0.59–1.01 0.06
eGFR indicates estimated glomerular filtration rate; MAC, mitral annular 
calcification; and OR, odds ratio.
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chronic kidney disease (P=0.933). There were no asso-
ciations with MAC progression for low-density lipopro-
tein (r=−0.10; P=0.444), HDL (high-density lipoprotein; 
r=−0.08, P=0.524) or lipoprotein(a) (r=0.07, P=0.629).
All 22 (36.7%) patients with baseline CT-MAC (CT+) 
demonstrated progression in their CT-MAC scores (me-
dian progression rate 199 [63–480] AU/y). Eight (21.1%) 
of the 38 patients without baseline CT-MAC (CT−) de-
veloped new MAC (CT-MAC score at second exam 135 
[40–291] AU). MAC regression was not observed. In a 
multiple linear regression model, baseline CT-MAC cal-
cium score (β=0.048 per 100 AU; P=0.013) was an inde-
pendent predictor of log-transformed MAC progression 
after adjustment for age (β=0.008 per year; P=0.847), 
sex (β=−0.580; P=0.368) and eGFR (β=−0.063 per 10 
mL/min; P=0.718).
Patients with increased mitral annular 18F-fluoride PET 
uptake demonstrated faster progression than patients 
without (CT-MAC progression: PET+ 200 [47–480] ver-
sus PET− 0 [0–3] AU/y; P<0.001). In multinomial logistic 
regression models adjusted for age and sex, there was a 
stronger association of positive 18F-fluoride PET uptake 
(PET+) with a MAC progression rate above median (OR, 
100.03; 95% CI 10.88–919.62; P<0.001), than below 
median (OR, 17.25; 95% CI 2.76–107.92; P=0.002). 
Similar results were obtained with 18F-fluoride uptake 
as continuous variable (MAC progression above me-
dian: OR, 1.95 per 0.1 increment in TBRmax; 95% CI 
1.38–2.75, P<0.001; MAC progression below median: 
OR, 1.71; 95% CI 1.23–2.37; P=0.001).
When considering PET and CT data together, 
PET−CT− patients did not demonstrate MAC progres-
sion (median MAC progression, 0 [0–0] AU/y, n=32), 
while MAC progression was highest in PET+CT+ 
patients (270 [68–493] AU/y, n=18). Intermediate pro-
gression was observed in PET+CT− (47 [0–95] AU/y, 
n=5) and PET−CT+ patients (102 [39–166] AU/y, n=4; 
Figure 3C).
DISCUSSION
We used state-of-the-art multimodality imaging to inves-
tigate MAC, providing novel insights into the pathophys-
iology of this common condition and factors associated 
with its prevalence, disease activity, and progression. We 
confirmed that MAC is characterized by both calcifica-
tion and inflammatory activity that increases propor-
tionally to the baseline MAC burden. Importantly, while 
female sex, renal dysfunction, and local inflammatory 
activity were associated with MAC disease activity, the 
strongest correlate was the local burden of calcium al-
ready present within the valve annulus. Similar observa-
tions were made with respect to progression, with the 
fastest progression observed in patients with the largest 
baseline burden of MAC. We, therefore, suggest that 
once established, MAC activity and progression are char-
acterized by a vicious cycle of established calcium, injury, 
and inflammation within the valve that prompts further 
calcification activity. These findings support the concept 
that therapeutic strategies targeting MAC will need fo-
cus on breaking this vicious calcification cycle.
Despite its high prevalence, contribution to mitral 
valve dysfunction and adverse prognosis,4 the patho-
biology of MAC remains incompletely understood. 
Moreover, therapeutic options are limited since effec-
tive medical therapy is lacking and surgical intervention 
is made complicated by its presence.24 There is, there-
Table 4. Correlations of Mitral Annular 18F-Fluoride and 18F-FDG PET 
Uptake (Disease Activity) With Imaging Findings in the Mitral Annulus 
(Local Factors) and Remote Regions, as Well as Serum Biomarker Levels 
(Remote Factors)
18F-Fluoride TBRmax
18F-FDG TBRmax
r Value P Value r Value P Value
Local factors
  Mitral annulus CT calcium 
score
0.78 <0.001 0.50 <0.001
  Mitral annulus 18F-fluoride 
TBRmax
… … 0.54 <0.001
  Mitral annulus 18F-FDG 
TBRmax
0.54 <0.001 … …
Remote factors
  Aortic valve CT calcium 
score
0.24 0.017 0.15 0.218
  Aortic valve 18F-fluoride 
TBRmax
0.19 0.053 −0.02 0.848
  Aortic valve 18F-FDG TBRmax −0.02 0.895 −0.05 0.658
  Coronary artery CT 
calcium score
0.03 0.789 0.12 0.327
  Coronary artery 18F-fluoride 
TBRmax
0.14 0.159 0.08 0.518
  Aorta CT calcium score 0.20 0.049 0.14 0.262
  Aorta 18F-fluoride TBRmax 0.23 0.025 −0.02 0.884
  Aorta 18F-FDG TBRmax −0.16 0.127 −0.23 0.060
  Bone mineral density −0.19 0.065 −0.15 0.247
  Bone 18F-fluoride TBRmax 0.02 0.861 0.01 0.989
Serum biomarkers
  Calcium 0.15 0.126 0.04 0.774
  Phosphate −0.02 0.828 0.14 0.260
  Alkaline phosphatase 0.11 0.264 −0.02 0.887
  Creatinine 0.07 0.494 −0.02 0.848
  LDL cholesterol −0.03 0.746 −0.30 0.014
  HDL cholesterol −0.04 0.677 −0.01 0.919
  Total cholesterol −0.07 0.500 −0.24 0.050
  Triglycerides −0.07 0.484 0.00 0.992
  Lipoprotein(a) 0.11 0.286 0.08 0.507
Data presented in study cohort patients (n=104). In 18F-FDG analyses, 
patients with failed myocardial suppression were excluded (n=33). CT 
indicates computed tomography; 18F-FDG, 18F-Fluorodeoxyglucose; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; PET, positron emission 
tomography; and TBRmax, tissue-to-background ratio.
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fore, an urgent need to illuminate the pathophysiol-
ogy underlying MAC and to identify novel therapeutic 
strategies to prevent its clinical sequelae.9 We describe 
a new multimodality imaging approach to help address 
this need. First, we have applied CT calcium scoring to 
define the presence of MAC and to quantify disease 
prevalence, burden, and progression. Second, we used 
18F-FDG to measure inflammatory activity. Although 
18F-FDG was only interpretable in two-thirds of patients, 
our data clearly demonstrate that MAC is an inflamma-
tory condition with the 18F-FDG PET signal increasing in 
proportion to baseline disease severity. Finally, we used 
18F-fluoride PET as marker of calcification activity dem-
onstrating a close association with subsequent progres-
sion and building upon a growing body of literature 
using 18F-fluoride to image developing cardiovascular 
microcalcification. The use of a cohort of patients with 
calcific aortic valve disease provided a patient popula-
tion at high risk of developing MAC, as evidenced by 
the particularly high prevalence. This gave us the op-
portunity to assess disease activity and progression in 
patients with established MAC, but also in patients who 
subsequently developed MAC during follow-up. It also 
provided insights into why certain patients with aortic 
stenosis develop MAC, while others do not, with fe-
male sex, renal impairment, and advanced AVC appear-
ing to be of particular importance in this population.
Factors Associated With Disease Activity 
in MAC
Using 18F-fluoride PET, we demonstrated that calcifica-
tion activity in the mitral annulus is closely related to the 
local inflammatory signal provided by 18F-FDG imaging. 
This is consistent with histological studies of excised 
mitral valves demonstrating increased expression of 
pro-calcific cells and mediators adjacent to T-lympho-
cytic infiltrates and suggests that calcium deposition 
is closely related to inflammatory activity.5,6 However, 
MAC activity was, in fact, most closely associated with 
the baseline CT-MAC calcium score. Similar results were 
observed for progression: patients with rapid disease 
progression and highest disease activity were those with 
the highest baseline CT calcium scores. Indeed, baseline 
MAC was the strongest predictor of MAC progression, 
here replicating the findings from the Multiethnic Study 
of Atherosclerosis.7
We believe our concordant data on MAC disease 
activity and progression have important therapeutic 
implications. The findings are remarkably similar to 
observations made in aortic stenosis, where it has been 
suggested that calcium within the valve increases me-
chanical stress and injury leading to inflammation and 
increased calcification activity.25 A similar self-perpetu-
ating cycle of calcification inducing further calcification 
Figure 1. Relationship of mitral annular calcification (MAC) 18F-fluoride activity, MAC calcium score, and 18F-FDG activity. 
MAC activity (18F-fluoride tissue-to-background ratio [TBRmax]) increased with the burden of baseline MAC (box plots by categories of baseline CT-MAC calcium 
score: zero/below median [<837 AU]/above median [≥837 AU]; A) and was correlated with inflammatory activity 18F-fluorodeoxyglucose (18F-FDG TBRmax; B). 
Baseline CT-MAC was virtually absent in patients without 18F-fluoride activity (C). CT indicates computed tomography.
Table 5. Factors Associated With Disease Activity in MAC
Model 1 (n=98) Model 2 (n=68)
β Value 95% CI P Value β Value 95% CI P Value
Age (per 10 y) −0.002 −0.070 to 0.066 0.953 0.065 −0.019 to 0.148 0.127
Male sex −0.172 −0.289 to −0.054 0.005 −0.082 −0.229 to 0.066 0.273
AVC (per 100 AU) 0.003 −0.000 to 0.005 0.052 0.002 −0.002 to 0.005 0.318
eGFR (per 10 mL/min) −0.032 −0.061 to −0.003 0.030 −0.001 −0.039 to 0.038 0.988
MAC (per 100 AU) 0.014 0.011 to 0.018 <0.001 0.010 0.005 to 0.015 <0.001
18F-FDG TBRmax (per 0.1) … … … 0.049 0.021 to 0.077 0.001
Predictors of log-transformed 18F-fluoride TBRmax in multiple linear regression model. Model 1 includes age, sex, hypertension, 
diabetes mellitus, smoking, LDL, prior cardiovascular disease, and variables with P>0.2 in bivariate comparisons, followed by 
backwards stepwise elimination process. Model 2 includes 18F-FDG TBRmax in addition to variables in model 1. AVC indicates aortic valve 
calcification; 18F-FDG, 18F-Fluorodeoxyglucose; MAC, mitral annular calcification; and TBRmax, tissue-to-background ratio.
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might also underlie MAC. The development of effective 
medical therapy in both conditions is, therefore, likely 
to require strategies that interrupt this cycle without 
impacting bone health. Studies are currently underway 
testing such therapies in patients with aortic stenosis 
(SALTIRE2, NCT02132026) providing an opportunity to 
investigate their impact on bystander MAC.
Study Limitations
Our study cohort comprised participants with calcific 
aortic valve disease. Although this ensured high propor-
tions of prevalent and incident MAC, our results may 
not directly apply to patients with isolated mitral valve 
disease or other conditions known to be associated 
with MAC. Moreover, our sample size was modest, pre-
cluding more detailed examination of determinants and 
consequences of microcalcification and inflammation. 
In addition, one-third of patients met criteria for failed 
myocardial FDG suppression and were excluded from 
the analysis of FDG data. Further studies exploring the 
role of PET-CT in larger samples and different patient 
populations are warranted. Such studies may benefit 
from the use of contrast CT to better investigate the 
spatial distribution of PET uptake within the mitral an-
nulus and to improve interobserver reproducibility. In 
addition, advanced imaging processing technologies 
such as adaptive thresholding may improve uptake de-
lineation, and ECG-gating of the PET acquisition may 
reduce image blurring because of cardiac motion.
Figure 2. Baseline computed tomography mitral annular calcification (CT-MAC), 18F-fluoride positron emission tomography (PET) activity, and 2-year 
progression in 3 patients.  
First row, Mild MAC at baseline (A), associated with mild mitral annular 18F-fluoride uptake (B) and modest progression after 2 y (change in CT-MAC 69 AU (C). 
Second row, Moderate MAC at baseline (A), moderate 18F-fluoride uptake (B), and intermediate progression after 2 y (change in CT-MAC 2404 AU (C). Third 
row, Severe MAC at baseline (A), bifocal high-intensity 18F-fluoride uptake (B), and rapid progression (change in CT-MAC 9446 AU (C). Note de novo areas of 
MAC that developed at the site of intense 18F-fluoride uptake in the lateral annulus.
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Conclusions
In this cohort, although female sex, renal dysfunction, 
and local inflammatory activity emerged as important 
determinants of disease activity in MAC, the strongest 
determinant was the baseline CT-MAC calcium score. 
Moreover, the higher the baseline burden of MAC, the 
higher the disease activity and the faster the rate of pro-
gression. This may reflect a vicious cycle of established 
calcium begetting further calcification within the mitral 
annulus that may be a suitable target of future therapies.
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